Plain-English translation of NCT06321939 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing a new way to measure cancer DNA in your blood using advanced sequencing technology. This study involves people with newly diagnosed nasopharyngeal cancer who are receiving standard treatment (chemotherapy and/or radiation). The goal is to see if this new blood test is better than older methods at tracking how well your treatment is working.
Currently, doctors use older blood tests to monitor nasopharyngeal cancer patients during treatment. This trial exists to see if a newer, more precise blood test could give doctors better information sooner about whether the treatment is working, which could help guide treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive your standard cancer treatment as planned. You would have blood drawn at three key time points: when you are first diagnosed, after two cycles of chemotherapy, and 4–8 weeks after finishing radiation therapy. Researchers will use these blood samples to test the new monitoring method. The study involves about 50 people total and does not add extra treatments—only blood draws alongside your regular care.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China